DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for hepatocellular adenoma — screening already-approved drugs against its 37-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHepatocellular adenoma maps to a 37-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hepatocellular adenoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ras homolog family member A (RHOA) — RHOA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gdpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5C4M · 1.3 Å · ligand GUANOSINE-5'-DIPHOSPHATE (GDP). Experimental structure, not a prediction.
What the evidence adds up to
A 2017 retrospective cohort study of 194 patients (192 women) with hepatocellular adenoma larger than 5 cm found that a six-month waiting period before deciding on resection is too early. Among 118 adenomas managed conservatively or treated more than six months after diagnosis, 69 (58.5 per cent) regressed to 5 cm or smaller after a median of 104 weeks. Larger adenomas took longer to regress. No complications were documented during follow-up. The authors suggest the cut-off for assessment could be prolonged to 12 months in women with typical, non-β-catenin-activated HCA, regardless of baseline diameter.
A 2009 surgical series reported that 3 of 28 patients (10.7 per cent) with hepatocellular adenoma presented with spontaneous rupture. All three had sudden abdominal pain and haemodynamic instability. Two were women with a history of oral contraceptive use; the third was a man. Surgical approaches included right hemihepatectomy, right extended hepatectomy, and non-anatomic resection. There were no deaths. Postoperative complications included bile leakage, wound infection, intraperitoneal abscess, and pleural effusion. The authors conclude that surgery can control haemorrhage and stabilise the patient, but the decision depends on the patient’s condition and surgical team expertise.
A 2008 retrospective analysis of 11 cases reported an average tumour diameter of 6.27 cm. Six patients had local excision, three had segmental liver resection, and two underwent left hepatectomy after transarterial chemoembolisation (TACE). All patients were followed for 5 to 232 months, with an average survival of 53.5 months. No relapse or metastasis was found. The authors state that surgical resection is an effective cure and that complete resection yields good prognosis.
A 2017 systematic review on benefits and harms of transarterial embolisation for treating hepatocellular adenoma was retracted due to inclusion of data accessible only during peer review for another journal. No conclusions from that review can be used.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
British journal of surgery · 2017 · 37 citations
Retrospective study on timing of resection of hepatocellular adenoma
AbstractBACKGROUND: Hepatocellular adenoma (HCA) is a benign liver tumour that may be complicated by bleeding or malignant transformation. Present guidelines advise cessation of oral contraceptives and surgical resection if the lesion is still larger than 5 cm at 6 months after diagnosis. The aim of this study was to evaluate whether this 6-month interval is sufficient to expect regression of a large HCA to 5 cm or smaller. METHODS: This retrospective cohort study included all patients with an HCA larger than 5 cm diagnosed between 1999 and 2015 with follow-up of at least 6 months. Medical records were reviewed for patient characteristics, clinical presentation, lesion characteristics, management and complications. Differences in characteristics were assessed between patients kept under surveillance and those who underwent treatment for an HCA larger than 5 cm. RESULTS: Some 194 patients were included, of whom 192 were women. Eighty-six patients were kept under surveillance and 108 underwent HCA treatment. Patients in the surveillance group had a significantly higher BMI (P = 0·029), smaller baseline HCA diameter (P < 0·001), more centrally located lesions (P < 0·001) and were more likely to have multiple lesions (P = 0·001) than those in the treatment group. There were no significant differences in sex, age at diagnosis, symptoms, complication rates and HCA subtype distribution. Time-to-event analysis in patients managed conservatively and those still undergoing treatment more than 6 months after diagnosis showed that 69 of 118 HCAs (58·5 per cent) regressed to 5 cm or smaller after a median of 104 (95 per cent c.i. 80-128) weeks. Larger HCAs took longer to regress (P < 0·001). No complications were documented during follow-up. CONCLUSION: This study suggests that a 6-month cut-off point for assessment of regression of HCA larger than 5 cm to no more than 5 cm is too early. As no complications were documented during follow-up, the cut-off point in women with typical, non-β-catenin-activated HCA could be prolonged to 12 months, irrespective of baseline diameter.
Surgical Management of Spontaneous Ruptured Hepatocellular Adenoma
AbstractAIMS: Spontaneous ruptured hepatocellular adenoma (SRHA) is a rare life-threatening condition that may require surgical treatment to control hemorrhaging and also stabilize the patient. We report a series of emergency surgeries performed at our institution for this condition. METHODS: We reviewed medical records and radiology files of 28 patients (from 1989 to 2006) with a proven diagnosis of hepatocellular adenoma (HA). Three (10.7%) of 28 patients had spontaneous ruptured hepatocellular adenoma, two of which were associated with intrahepatic hemorrhage while one had intraperitoneal bleeding. Two patients were female and one was male. Both female patients had a background history of oral contraceptive use. Sudden abdominal pain associated with hemodynamic instability occurred in all patients who suffered from spontaneous ruptured hepatocellular adenoma. The mean age was 41.6 years old. The preoperative assessment included liver function tests, ultrasonography and computed tomography. RESULTS: The surgical approaches were as follows: right hemihepatectomy for controlling intraperitoneal bleeding, and right extended hepatectomy and non-anatomic resection of the liver for intrahepatic hemorrhage. There were no deaths, and the postoperative complications were bile leakage and wound infection (re-operation), as well as intraperitoneal abscess (re-operation) and pleural effusion. CONCLUSION: Spontaneous ruptured hepatocellular adenoma may be treated by surgery for controlling hemorrhages and stabilizing the patient, and the decision to operate depends upon both the patient's condition and the expertise of the surgical team.
<i>Retracted:</i> Systematic review: benefits and harms of transarterial embolisation for treating hepatocellular adenoma
AbstractThe above article 1 from Alimentary Pharmacology & Therapeutics, published online on 20 March 2017 in Wiley OnlineLibrary ( www.onlinelibrary.wiley.com ) has been retracted by agreement between the Authors, the Editor‐in‐Chief, R.E. Pounder, and John Wiley & Sons Ltd. The retraction has been agreed due to the inclusion of data accessible only during peer review for another journal. REFERENCE 1. Zhao C, Pei S‐L, Cucchetti A, et al. Systematic review: benefits and harms of transarterial embolisation for treating hepatocellular adenoma. Aliment Pharmacol Ther . 2017. https://doi.org/10.1111/apt.14044
AbstractObjective To study the clinicopathological characteristics, the procedure of diagnosis and treatment and prognosis of hepatocellular adenoma. Methods The clinicopathological data and prognoses of 11 cases of hepatocellular adenoma treated in our hospital from January 1 989 to March 2006 were retrospectively analyzed. Results There was no specific symptom among the patients. The average diameter of the tumors was 6.27 cm. Loeal excision was performed in 6 cases. Segmental excision of the liver was performed in 3 patients. Two patients underwent left hepatectomy after TACE. All patients were followed up for 5-232 months and the average survival time was 53.5 months. No evidence of relapse and metastasis in these patients was found. Conclusion Hepatocellular adenoma is a rare kind of benign tumor of the liver and surgical resection is the effective way to cure it. The choice of surgical procedures depends on the location and size of the tumor. Complete resection results in good prognosis.
Key words:
Liver neoplasms; Diagnosis; Treatment; Prognosis
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
